07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

Architect AFP regulatory update

FDA approved Abbott's Architect AFP test as an aid in monitoring disease progression in patients with nonseminomatous testicular cancer and an aid in detecting fetal open neural tube defects (NTD). The chemiluminescent microparticle immunoassay (CMIA),...